Literature DB >> 1696650

Effects of endothelin-1 in isolated perfused rat heart.

S Neubauer1, G Ertl, U Haas, F Pulzer, K Kochsiek.   

Abstract

We examined the effects of the vasoconstrictor peptide endothelin-1 in the isolated heart and defined interactions of endothelin-1 with other hormone systems. Isolated isovolumic rat hearts were perfused with Krebs-Henseleit buffer at constant pressure. First, the effect of a single bolus of endothelin-1 (4-400 pmol) was followed for 90 min. The effect of high dosages (40 and 400 pmol) of endothelin-1 on coronary flow was biphasic, with an early vasodilator and a late vasoconstrictor component that was irreversible. Second, cumulative dose-response curves were obtained for endothelin-1 boluses of 0.04-400 pmol. Coronary flow declined with increasing dosages and was almost abolished at 400 pmol. Neither alpha- nor beta-blocking agents (phentolamine and propranolol) nor the Ca2(+)-channel blocker nifedipine altered the effects of endothelin-1, but prostaglandin synthesis inhibition by indomethacin significantly augmented vasoconstriction by endothelin-1. Angiotensin-converting enzyme (ACE) inhibition by captopril antagonized endothelin-1-dependent vasoconstriction to a small extent at 400 pmol. Coronary constriction due to endothelin-1 could not be reversed by nitroglycerin. We conclude that in isolated rat heart endothelin-1 causes marked and long-lasting coronary constriction. The effect is not influenced by sympathetic and Ca2(+)-channel blockade, is enhanced by prostaglandin synthesis inhibition, and is reduced by ACE inhibition.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696650     DOI: 10.1097/00005344-199007000-00001

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

1.  Exercise limits the production of endothelin in the coronary vasculature.

Authors:  Vincent J de Beer; Shawn B Bender; Yannick J Taverne; Fen Gao; Dirk J Duncker; M Harold Laughlin; Daphne Merkus
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-11       Impact factor: 4.733

Review 2.  Role of endothelin in hypertension.

Authors:  B K Krämer; M Ackermann; S M Kohler; G A Riegger
Journal:  Clin Investig       Date:  1994-01

3.  Effects of KRN2391, nicorandil and diltiazem on the changes in the electrocardiogram caused by endothelin-1 in anaesthetized rats.

Authors:  K Harada; A Miwa; S Kaneta; T Izawa; H Fukushima; N Ogawa
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

4.  The effects of the endothelin ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion.

Authors:  L McMurdo; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

5.  Comparison of the contractile effects of endothelin-1 and sarafotoxin S6b in goat isolated cerebral arteries.

Authors:  J B Salom; G Torregrosa; F J Miranda; J A Alabadí; E Alborch
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

Review 6.  Endothelin receptor antagonists in heart failure: current status and future directions.

Authors:  Georg Ertl; Johann Bauersachs
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Endothelin and myocardial ischemia.

Authors:  D Hasdai; R Kornowski; A Battler
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

8.  Hemodynamic and inotropic effects of endothelin-1 in vivo.

Authors:  M E Beyer; S Nerz; B K Krämer; H M Hoffmeister
Journal:  Basic Res Cardiol       Date:  1994 Jan-Feb       Impact factor: 17.165

9.  Modulation by aging of the coronary vascular response to endothelin-1 in the rat isolated perfused heart.

Authors:  Y Katano; A Ishihata; S Morinobu; M Endoh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

10.  Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction.

Authors:  S Neubauer; M Horn; A Naumann; R Tian; K Hu; M Laser; J Friedrich; P Gaudron; K Schnackerz; J S Ingwall
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.